S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
|ClinicalTrials.gov Identifier: NCT01120262|
Recruitment Status : Completed
First Posted : May 10, 2010
Last Update Posted : October 7, 2016
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Genetic: gene expression analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- To test the association between serum PSA response (< 4 ng/mL) at 7 months with inherited variability of germline single nucleotide polymorphisms, in a set of candidate genes, in patients with metastatic prostate cancer treated with combination induction androgen-deprivation therapy comprising bicalutamide and goserelin.
OUTLINE: DNA extracted from whole blood or serum samples is analyzed for inherited variability of germline single nucleotide polymorphisms.
|Study Type :||Observational|
|Actual Enrollment :||545 participants|
|Official Title:||Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
- Serum PSA values at 7 months [ Time Frame: 7 months ]
- Role of genetic variation in response to therapy [ Time Frame: baseline ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01120262
|Principal Investigator:||Kathleen A. Cooney, MD||University of Michigan Cancer Center|